Y Intercept Hong Kong Ltd Invests $1.40 Million in Keros Therapeutics, Inc. $KROS

Y Intercept Hong Kong Ltd bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 104,878 shares of the company’s stock, valued at approximately $1,400,000. Y Intercept Hong Kong Ltd owned about 0.26% of Keros Therapeutics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in KROS. CWM LLC raised its holdings in Keros Therapeutics by 10,157.7% in the 1st quarter. CWM LLC now owns 2,667 shares of the company’s stock valued at $27,000 after buying an additional 2,641 shares during the last quarter. Corton Capital Inc. bought a new position in Keros Therapeutics in the 1st quarter valued at approximately $186,000. Federated Hermes Inc. raised its holdings in Keros Therapeutics by 882.3% in the 1st quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock valued at $12,474,000 after buying an additional 1,099,519 shares during the last quarter. XTX Topco Ltd bought a new position in Keros Therapeutics in the 1st quarter valued at approximately $490,000. Finally, Vanguard Group Inc. raised its holdings in Keros Therapeutics by 31.1% in the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after buying an additional 609,212 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on KROS shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company started coverage on shares of Keros Therapeutics in a report on Monday, October 20th. They issued an “overweight” rating and a $26.00 price objective for the company. Finally, HC Wainwright dropped their price objective on shares of Keros Therapeutics from $25.00 to $20.00 and set a “buy” rating for the company in a report on Friday, August 8th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and an average price target of $30.00.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $15.22 on Monday. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The firm has a 50 day moving average price of $15.43 and a two-hundred day moving average price of $14.58. The firm has a market cap of $463.75 million, a price-to-earnings ratio of 49.10, a PEG ratio of 1.96 and a beta of 1.12.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a net margin of 8.06% and a return on equity of 2.96%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $3.83 million. During the same quarter last year, the business earned ($1.25) EPS. The company’s revenue was up 49002.7% compared to the same quarter last year. As a group, equities research analysts predict that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Activity at Keros Therapeutics

In other news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $95,659,436.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. 22.90% of the stock is currently owned by company insiders.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.